The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease
Abstract
The Movement Disorder Society Task Force for Rating Scales for Parkinson's disease (PD) prepared a critique of the Hoehn and Yahr scale (HY). Strengths of the HY scale include its wide utilization and acceptance. Progressively higher stages correlate with neuroimaging studies of dopaminergic loss, and high correlations exist between the HY scale and some standardized scales of motor impairment, disability, and quality of life. Weaknesses include the scale's mixing of impairment and disability and its non‐linearity. Because the HY scale is weighted heavily toward postural instability as the primary index of disease severity, it does not capture completely impairments or disability from other motor features of PD and gives no information on nonmotor problems. Direct clinimetric testing of the HY scale has been very limited, but the scale fulfills at least some criteria for reliability and validity, especially for the midranges of the scale (Stages 2–4). Although a “modified HY scale” that includes 0.5 increments has been adopted widely, no clinimetric data are available on this adaptation. The Task Force recommends that: (1) the HY scale be used in its original form for demographic presentation of patient groups; (2) when the HY scale is used for group description, medians and ranges should be reported and analysis of changes should use nonparametric methods; (3) in research settings, the HY scale is useful primarily for defining inclusion/exclusion criteria; (4) to retain simplicity, clinicians should “rate what you see” and therefore incorporate comorbidities when assigning a HY stage; and (5) because of the wide usage of the modified HY scale with 0.5 increments, this adaptation warrants clinimetric testing. Without such testing, however, the original five‐point scales should be maintained. © 2004 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Self-citation(1976) · Medical Entomology and Zoology · Cited by 8,899
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,810
JENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321
Variable expression of Parkinson's disease: A base‐line analysis of the DAT ATOP cohort
Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanow, C., Shoulson, I., et al. (1990) · Neurology · doi:10.1212/wnl.40.10.1529 · Cited by 1,285
Self-citationPramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Self-citationUnified Parkinson's disease rating scale characteristics and structure
Martínez‐Martín, P., Gil‐Nagel, A., Gracia, L. M., Gómez, J. B., Martínez‐Sarriés, J., Bermejo, F., & The Cooperative Multicentric Group (1994) · Movement Disorders · doi:10.1002/mds.870090112 · Cited by 796
The Prevention of Acute Gastric Ulcer in the Rat by α-Methyldopa
Djahanguiri, B., Hemmati, S., Sadeghi, D., & Firouzabadi, A. (1967) · Pharmacology · doi:10.1159/000137111 · Cited by 783
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Systematic evaluation of rating scales for impairment and disability in Parkinson's disease
Ramaker, C., Marinus, J., Stiggelbout, A. M., & van Hilten, B. J. (2002) · Movement Disorders · doi:10.1002/mds.10248 · Cited by 666
Price, D. D., Milling, L. S., Kirsch, I., Duff, A., Montgomery, G. H., & Nicholls, S. S. (1999) · Pain · doi:10.1016/s0304-3959(99)00081-0 · Cited by 561
Critical analysis of the disability in Parkinson's disease.
Webster, D. D. (1968) · PubMed · Cited by 488
The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years
Hely, M. A., Morris, J. G. L., Traficante, R., Reid, W. G. J., O'Sullivan, D. J., & Williamson, P. M. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.3.300 · Cited by 377
Clinically significant changes in pain along the visual analog scale
Bird, S. B., & Dickson, E. W. (2001) · Annals of Emergency Medicine · doi:10.1067/mem.2001.118012 · Cited by 368
Schrag, A. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.1.67 · Cited by 327
Shannon, K. M., Bennett, J. P., Friedman, J. H., & the Pramipexole Study Group (1997) · Neurology · doi:10.1212/wnl.49.3.724 · Cited by 281
Lieberman, A., Ranhosky, A., & Korts, D. (1997) · Neurology · doi:10.1212/wnl.49.1.162 · Cited by 268
A METHOD FOR EVALUATING DISABILITY IN PATIENTS WITH PARKINSONʼS DISEASE
CANTER, G. J., de La TORRE, R., & MIER, M. (1961) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196108000-00010 · Cited by 220
Vingerhoets, F. J. G., Snow, B. J., Lee, C. S., Schulzer, M., Mak, E., & Calne, D. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360512 · Cited by 218
Guttman, M., & International Pramipexole-Bromocriptine Study Group (1997) · Neurology · doi:10.1212/wnl.49.4.1060 · Cited by 209
Factor structure of the unified Parkinson's disease rating scale: Motor examination section
Stebbins, G. T., & Goetz, C. G. (1998) · Movement Disorders · doi:10.1002/mds.870130404 · Cited by 201
Self-citationManagement of Parkinson's disease: An evidence-based review
Lang, A. E., & Lees, A. (2002) · Movement Disorders · doi:10.1002/mds.5554 · Cited by 184
Pinter, M. M., Pogarell, O. M., & Oertel, W. H. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.4.436 · Cited by 155
van Hilten, J. J., van der Zwan, A. D., Zwinderman, A. H., & Roos, R. A. C. (1994) · Movement Disorders · doi:10.1002/mds.870090113 · Cited by 136
Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET.
Eidelberg, D., Moeller, J. R., Ishikawa, T., DHAWAN, V. M., Spetsieris, P. G., Chaly, T., Robeson, W., Dahl, J., & Margouleff, D. (1995) · PubMed · Cited by 136
Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study
Müller, J. W., Wenning, G. K., Jellinger, K. A., McKee, A. C., Poewe, W. H., & Litvan, I. (2000) · Neurology · doi:10.1212/wnl.55.6.888 · Cited by 120
Self-citationDevelopment and testing of the Parkinson's disease quality of life scale
Welsh, M. D., McDermott, M., Holloway, R. G., Plumb, S., Pfeiffer, R. F., & Hubble, J. P. (2003) · Movement Disorders · doi:10.1002/mds.10424 · Cited by 117
Self-citationClinical course of patients with idiopathic Parkinson's disease
Roos, R. A. C., Jongen, J. C. F., & van der Velde, E. A. (1996) · Movement Disorders · doi:10.1002/mds.870110304 · Cited by 112
The natural history of Parkinson's disease
Poewe, W. H., & Wenning, G. K. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.146s · Cited by 111
Self-citationDifferential progression of motor impairment in levodopa-treated Parkinson's disease
Goetz, C. G., Stebbins, G. T., & Blasucci, L. M. (2000) · Movement Disorders · Cited by 91
Self-citationStebbins, G. T., Goetz, C. G., Lang, A. E., & Cubo, E. (1999) · Movement Disorders · Cited by 84
Self-citationEvaluation of the Short Parkinsonʼs Evaluation Scale
Rabey, J. M., Bass, H., Bonuccelli, U., Brooks, D. J., Klotz, P., Korczyn, A. D., Kraus, P., Martinez-Martin, P., Morrish, P., Sauten, W. V., et al. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199708000-00004 · Cited by 77
Henderson, L., Kennard, C., Crawford, T. J., Day, S., Everitt, B. J., Goodrich, S. J., Jones, F., & Park, D. M. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.1.18 · Cited by 74
DISABILITY AND PROGRESSION IN PARKINSON'S DISEASE
Marttila, R. J., & Rinne, U. K. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1977.tb01420.x · Cited by 66
Reliability of the columbia scale for assessing signs of parkinson's disease
Hely, M. A., Chey, T., Wilson, A. J., Williamson, P. M., O'Sullivan, D. J., Rail, D., & Morris, J. G. L. (1993) · Movement Disorders · doi:10.1002/mds.870080409 · Cited by 61
Evaluating the evaluations: Or how to weigh the scales of parkinsonian disability
Diamond, S. G., & Markham, C. H. (1983) · Neurology · doi:10.1212/wnl.33.8.1098 · Cited by 52
Geminiani, G. C., Cesana, B. M., Tamma, F., Contri, P., Pacchetti, C., Carella, F., Piolti, R., Martignoni, E., Giovannini, P., Girotti, F., et al. (1991) · Movement Disorders · doi:10.1002/mds.870060411 · Cited by 47
Evaluating drug treatments for Parkinson's disease: how good are the trials?
Wheatley, K., Stowe, R. L., Clarke, C. E., Hills, R. K., Williams, A. C., & Gray, R. G. (2002) · BMJ · doi:10.1136/bmj.324.7352.1508 · Cited by 43
Evaluation of Parkinson’s Disease: Reliability of Three Rating Scales
Ginanneschi, A., Degl'Innocenti, F., Magnolfi, S., Maurello, M. T., Catarzi, L., Marini, P., & Amaducci, L. A. (1987) · Neuroepidemiology · doi:10.1159/000110159 · Cited by 40
Quantification of motor deficit in Parkinson's disease with a motor performance test series
Pinter, M. M., Helscher, R. J., Našel, C., Riedl, E., & Schnaberth, G. (1992) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02251476 · Cited by 30
Evaluation of Parkinson's Disease: A New Approach to Disability
Ginanneschi, A., Degl'Innocenti, F., Maurello, M. T., Magnolfi, S., Marini, P., & Amaducci, L. A. (1991) · Neuroepidemiology · doi:10.1159/000110285 · Cited by 17
Cited by
Dorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
The genetic architecture of Parkinson's disease
Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30287-x · Cited by 1,114
Metadata
- Authors
- Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., Giladi, N., Holloway, R. G., Moore, C. G., Wenning, G. K., Yahr, M. D., & Seidl, L.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2004-08-30
- Volume
- 19
- Issue
- 9
- Pages
- 1020-1028
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2126008330
- Cited by
- 2,347
- References
- 44
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.